Viral Conjunctivitis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Viral Conjunctivitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Viral Conjunctivitis - Pipeline Review, H2 2016', provides an overview of the Viral Conjunctivitis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Viral Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
- The report reviews pipeline therapeutics for Viral Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Viral Conjunctivitis therapeutics and enlists all their major and minor projects
- The report assesses Viral Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Viral Conjunctivitis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Viral Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Viral Conjunctivitis - Overview 7
Viral Conjunctivitis - Therapeutics under Development by Companies 8
Viral Conjunctivitis - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Viral Conjunctivitis - Products under Development by Companies 11
Viral Conjunctivitis - Companies Involved in Therapeutics Development 12
Adenovir Pharma AB 12
NanoViricides, Inc. 13
Panoptes Pharma Ges.m.b.H. 14
Shire Plc 15
Starpharma Holdings Limited 16
Viral Conjunctivitis - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 25
APD-209 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
APD-514 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
astodrimer - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
EKCCide-I - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
PP-001 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
SHP-640 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Viral Conjunctivitis - Dormant Projects 36
Viral Conjunctivitis - Discontinued Products 37
Viral Conjunctivitis - Product Development Milestones 38
Featured News & Press Releases 38
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 38
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis 38
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis 39
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 39
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Number of Products under Development for Viral Conjunctivitis, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2016 12
Viral Conjunctivitis - Pipeline by NanoViricides, Inc., H2 2016 13
Viral Conjunctivitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2016 14
Viral Conjunctivitis - Pipeline by Shire Plc, H2 2016 15
Viral Conjunctivitis - Pipeline by Starpharma Holdings Limited, H2 2016 16
Assessment by Monotherapy Products, H2 2016 17
Number of Products by Stage and Target, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 24
Viral Conjunctivitis - Dormant Projects, H2 2016 36
Viral Conjunctivitis - Discontinued Products, H2 2016 37